Clinical trial · no report yet · Phase 3
CAPItello-292
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT04862663 ↗
- Active not recruiting
- AstraZeneca
- 31 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 15 | |
| Podcasts | 13 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Locally Advanced (Inoperable) or Metastatic Breast Cancer
- Interventions
- Capivasertib; Fulvestrant; Palbociclib; Ribociclib; Abemaciclib
- Arms
- Capivasertib Plus Palbociclib and Fulvestrant · Experimental
- Capivasertib Plus Ribociclib and Fulvestrant · Experimental
- Capivasertib Plus Abemaciclib and Fulvestrant · Experimental
- Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib) · Experimental
- Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib) · Active comparator
- Enrollment
- 893
- Primary outcomes
- Phase Ib: 1. The number of participants with dose-limiting toxicity, as defined in the protocol.
- Phase Ib: 2. The number of participants with treatment-related adverse events.
- Phase Ib: 3. The number of participants with treatment-related serious adverse events.
- Phase III: 1. Progression Free Survival (PFS).
- Sponsor
- AstraZeneca
- Start
- May 10, 2021
- Primary completion
- Nov 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04862663 · updated Aug 17, 2026